New Nano-Drug enters human testing for tough cancers
NCT ID NCT04640480
Summary
This early-stage study tested a new nanoparticle form of a cancer drug called SNB-101 in 21 patients with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and see how the body processes the drug. Patients received the drug through an IV every two weeks until their cancer progressed or side effects became too severe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHA Medical Center
Seongnam-si, Gyeonggi-do, 13496, South Korea
-
The Catholic University of Korea Seoul ST. Mary's Hospital
Seoul, Seoul, 06591, South Korea
-
The Severance Hospital of the Yonsei University
Seoul, Seoul, 03722, South Korea
Conditions
Explore the condition pages connected to this study.